Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-06-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
独立董事关于第六届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including stock price stabilization, share repurchase, and amendments to the company's articles of association. It references compliance with company law, securities law, and stock exchange listing rules. The document is a formal opinion related to board decisions rather than a full report or financial statement. It does not contain financial data or earnings information, nor is it a regulatory announcement or proxy solicitation. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and management decisions.
2023-06-19 Chinese
公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for Beijing Xinghao Pharmaceutical Co., Ltd., dated June 2023. It includes comprehensive provisions on company organization, shareholder rights, board and management structure, share issuance and transfer, shareholder meetings, voting rights, and other governance matters. It references relevant laws and regulations such as the Company Law of the People's Republic of China and securities regulations. The content is focused on governance rules and procedures rather than financial results, audit opinions, or meeting presentations. It is not an announcement or a brief notice but a substantive governance document. Therefore, the document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-06-19 Chinese
回购股份方案公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding a share repurchase plan by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics about the purpose, method, price, quantity, funding source, implementation period, and impact analysis of the share buyback. It also discusses authorization by the shareholders' meeting and risks related to the repurchase. The content is focused on the company's plan to buy back its own shares and does not contain financial statements or earnings data. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares. The document length is about 4990 characters, which is sufficient for a full announcement rather than a brief notice. Therefore, the correct classification is POS with high confidence.
2023-06-19 Chinese
关于实施稳定股价方案的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding the implementation of a stock price stabilization plan involving share repurchase. It details the conditions triggering the plan, the repurchase method, price limits, expected share quantities, and constraints on the company and its controlling shareholders. The document is a formal announcement about a capital action (share repurchase) to stabilize stock price, not a financial report or earnings release. It does not contain financial statements or earnings data but focuses on the share repurchase plan and related governance. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers share buybacks or repurchases.
2023-06-19 Chinese
关于召开 2023 年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2023 first extraordinary general meeting of shareholders (临时股东大会) for Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed, and procedural information for shareholders. It does not contain any financial statements or results, nor is it a transcript or report of the meeting outcomes. The document is relatively short (2664 characters) and serves as an announcement for the meeting rather than the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-06-19 Chinese
监事换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and change of the supervisory board members (监事换届公告) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the election of new supervisors, their terms, qualifications, and the impact of these changes on the company. There is no financial data, no mention of financial results, no audit information, no voting results, and no mention of any report publication. The content clearly relates to changes in company governance personnel, specifically the supervisory board, which falls under Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming it is not a full report or other category.
2023-06-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.